Trials / Completed
CompletedNCT00811876
Retrospective, Non-interventional Study of Depo-Eligard®.
Monitoring Tolerance, Safety and Acceptance of Depo-Eligard® in an Open Label, Retrospective, Non-interventional Clinical Trial
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 140 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study will evaluate the real-world effectiveness of Depo-Eligard® after six months of treatment
Detailed description
The study will provide data on the tolerance, safety and acceptance of Depo-Eligard® (leuproreline acetate) when used in routine clinical practice. Data on efficacy parameters such as testosterone, PSA levels, symptoms and treatment failure, if available will be collected.It will reflect the way Depo-Eligard® is used in routine clinical practice and how PSA, testosterone levels, symptoms and treatment failure, are used as parameters in the treatment for Prostate Cancer. Patient data will be collected after a treatment period of six months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Data Collection on Depo-Eligard exposure | Retrospective, Non-interventional |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2008-12-19
- Last updated
- 2010-01-22
Locations
23 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00811876. Inclusion in this directory is not an endorsement.